West Pharmaceutical Services, Inc. (NYSE:WST) Plans Quarterly Dividend of $0.18

West Pharmaceutical Services, Inc. (NYSE:WSTGet Rating) declared a quarterly dividend on Wednesday, February 23rd, Zacks reports. Shareholders of record on Wednesday, April 20th will be paid a dividend of 0.18 per share by the medical instruments supplier on Wednesday, May 4th. This represents a $0.72 annualized dividend and a yield of 0.19%. The ex-dividend date is Tuesday, April 19th.

West Pharmaceutical Services has a dividend payout ratio of 7.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect West Pharmaceutical Services to earn $10.35 per share next year, which means the company should continue to be able to cover its $0.72 annual dividend with an expected future payout ratio of 7.0%.

Shares of NYSE WST opened at $381.22 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.30 and a current ratio of 2.93. West Pharmaceutical Services has a 52-week low of $301.16 and a 52-week high of $475.35. The firm has a 50 day moving average price of $392.53 and a two-hundred day moving average price of $410.58. The stock has a market cap of $28.32 billion, a P/E ratio of 43.82, a price-to-earnings-growth ratio of 4.27 and a beta of 1.06.

West Pharmaceutical Services (NYSE:WSTGet Rating) last announced its quarterly earnings results on Thursday, February 17th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.92 by $0.12. West Pharmaceutical Services had a net margin of 23.37% and a return on equity of 31.20%. The firm had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $710.20 million. During the same period in the prior year, the company posted $1.34 EPS. The company’s revenue was up 26.0% on a year-over-year basis. Analysts predict that West Pharmaceutical Services will post 9.28 earnings per share for the current fiscal year.

Several research firms have recently weighed in on WST. William Blair reiterated an “outperform” rating on shares of West Pharmaceutical Services in a research report on Tuesday, February 22nd. Zacks Investment Research cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $450.00 price objective for the company. in a research report on Saturday, January 8th. Finally, StockNews.com cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Sunday, April 10th.

In other West Pharmaceutical Services news, VP Quintin J. Lai sold 8,016 shares of the firm’s stock in a transaction on Monday, March 14th. The shares were sold at an average price of $371.69, for a total value of $2,979,467.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.66% of the company’s stock.

A number of large investors have recently bought and sold shares of WST. Monolith Advisors acquired a new stake in West Pharmaceutical Services in the fourth quarter worth $29,000. EverSource Wealth Advisors LLC acquired a new stake in West Pharmaceutical Services in the fourth quarter worth $67,000. Forum Financial Management LP purchased a new position in West Pharmaceutical Services during the fourth quarter valued at approximately $281,000. Horizon Investments LLC grew its stake in West Pharmaceutical Services by 100.0% during the fourth quarter. Horizon Investments LLC now owns 1,136 shares of the medical instruments supplier’s stock valued at $533,000 after acquiring an additional 568 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in West Pharmaceutical Services during the fourth quarter valued at approximately $750,000. Institutional investors and hedge funds own 91.24% of the company’s stock.

West Pharmaceutical Services Company Profile (Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Articles

Dividend History for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.